EP0486526B2
(de)
|
1989-08-07 |
2001-03-07 |
Peptech Limited |
Bindeligande für tumornekrosisfaktor
|
US20030225254A1
(en)
*
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
US5959087A
(en)
*
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
ZA95960B
(en)
*
|
1994-03-14 |
1995-10-10 |
Genetics Inst |
Use of interleukin-12 antagonists in the treatment of autoimmune diseases
|
US6706264B1
(en)
*
|
1994-03-14 |
2004-03-16 |
Genetics Institute, Llc |
Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
|
US20010055581A1
(en)
|
1994-03-18 |
2001-12-27 |
Lawrence Tamarkin |
Composition and method for delivery of biologically-active factors
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
HU228630B1
(en)
*
|
1996-02-09 |
2013-04-29 |
Abbott Biotech Ltd |
Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
|
US7129061B1
(en)
*
|
1996-08-07 |
2006-10-31 |
Biogen Idec Ma Inc. |
Tumor necrosis factor related ligand
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
CA2288994C
(en)
*
|
1997-04-30 |
2011-07-05 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
US7229841B2
(en)
|
2001-04-30 |
2007-06-12 |
Cytimmune Sciences, Inc. |
Colloidal metal compositions and methods
|
US6407218B1
(en)
|
1997-11-10 |
2002-06-18 |
Cytimmune Sciences, Inc. |
Method and compositions for enhancing immune response and for the production of in vitro mabs
|
US7067144B2
(en)
*
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
US7553487B2
(en)
|
1998-12-14 |
2009-06-30 |
Genetics Institute, Llc |
Method and compositions for treating asthma
|
ES2277460T3
(es)
|
1998-12-14 |
2007-07-01 |
Genetics Institute, Llc |
Cadena del receptor de la citoquina.
|
JP2002538170A
(ja)
*
|
1999-03-02 |
2002-11-12 |
セントコール, インコーポレイテッド |
喘息の治療における抗−TNFα抗体
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
AU7912600A
(en)
*
|
1999-10-06 |
2001-05-10 |
Basf Aktiengesellschaft |
Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
|
WO2001058956A2
(en)
|
2000-02-10 |
2001-08-16 |
Abbott Laboratories |
Antibodies that bind human interleukin-18 and methods of making and using
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
CN101525384A
(zh)
|
2000-06-29 |
2009-09-09 |
艾博特公司 |
双特异性抗体及其制备方法和用途
|
UA81743C2
(uk)
*
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
WO2002051438A2
(en)
|
2000-12-22 |
2002-07-04 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
US20090137416A1
(en)
|
2001-01-16 |
2009-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating Cells Expressing Secreted Proteins
|
CA2434802C
(en)
*
|
2001-01-16 |
2013-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
WO2002076196A1
(en)
|
2001-03-22 |
2002-10-03 |
Abbott Gmbh & Co. Kg |
Transgenic animals expressing antibodies specific for genes of interest and uses thereof
|
US6410955B1
(en)
*
|
2001-04-19 |
2002-06-25 |
Micron Technology, Inc. |
Comb-shaped capacitor for use in integrated circuits
|
CA2817619A1
(en)
*
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
WO2003002187A2
(en)
*
|
2001-06-26 |
2003-01-09 |
Photomed Technologies, Inc. |
Multiple wavelength illuminator
|
TR201809008T4
(tr)
|
2001-06-26 |
2018-07-23 |
Amgen Fremont Inc |
Opgl ye karşi antikorlar.
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
AU2002341766A1
(en)
*
|
2001-09-20 |
2003-04-01 |
Genstar Therapeutics Corporation |
Improved methods for treatment with viral vectors
|
US20030065382A1
(en)
*
|
2001-10-02 |
2003-04-03 |
Fischell Robert E. |
Means and method for the treatment of coronary artery obstructions
|
EP1432431B1
(de)
|
2001-10-04 |
2017-05-10 |
Genetics Institute LLC |
Verfahren und zusammensetzungen zur modulierung der wirkung des interleukin-21
|
AU2003218432A1
(en)
*
|
2002-03-26 |
2003-10-13 |
Centocor, Inc. |
Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
|
US20030206898A1
(en)
*
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US20040009172A1
(en)
*
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US20090280065A1
(en)
*
|
2006-04-10 |
2009-11-12 |
Willian Mary K |
Uses and Compositions for Treatment of Psoriasis
|
US20070202104A1
(en)
*
|
2002-07-19 |
2007-08-30 |
Abbott Laboratories S.A. |
Treatment of spondyloarthropathies using TNFalpha inhibitors
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
AU2003265361A1
(en)
*
|
2002-08-28 |
2004-03-19 |
Pharmacia Corporation |
Stable ph optimized formulation of a modified antibody
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
NZ563471A
(en)
|
2002-11-08 |
2009-04-30 |
Ablynx Nv |
Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
US20040101939A1
(en)
*
|
2002-11-22 |
2004-05-27 |
Santora Ling C. |
Method for reducing or preventing modification of a polypeptide in solution
|
US20040162414A1
(en)
*
|
2002-11-22 |
2004-08-19 |
Santora Ling C. |
Method for reducing or preventing modification of a polypeptide in solution
|
EP1578799B8
(de)
|
2002-12-02 |
2011-03-23 |
Amgen Fremont Inc. |
Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
|
JP2006517191A
(ja)
*
|
2002-12-30 |
2006-07-20 |
アムジエン・インコーポレーテツド |
共刺激因子を用いた併用療法
|
US7101978B2
(en)
*
|
2003-01-08 |
2006-09-05 |
Applied Molecular Evolution |
TNF-α binding molecules
|
JP2007525409A
(ja)
*
|
2003-01-08 |
2007-09-06 |
アプライド モレキュラー エボリューション,インコーポレイテッド |
TNF−α結合分子
|
AU2004204262B2
(en)
*
|
2003-01-10 |
2010-11-04 |
Ablynx N.V. |
Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
NZ542306A
(en)
|
2003-03-14 |
2008-04-30 |
Wyeth Corp |
Antibodies against human IL-21 receptor and uses therefor
|
EP1460088A1
(de)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
|
WO2004098578A2
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
|
FR2856075B1
(fr)
*
|
2003-06-16 |
2007-10-12 |
Monoclonal Antibodies Therapeu |
Procede essentiellement automatise de criblage a grande echelle de cellules secretant des anticorps monoclonaux
|
FR2859725B1
(fr)
*
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
KR100772800B1
(ko)
*
|
2003-11-17 |
2007-11-01 |
주식회사유한양행 |
인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
|
JP2008504216A
(ja)
|
2003-12-02 |
2008-02-14 |
サイトイミューン サイエンシズ インコーポレイテッド |
モノクローナル抗体の生成のための方法および組成物
|
LT2805728T
(lt)
|
2003-12-23 |
2020-05-25 |
Genentech, Inc. |
Nauji anti-il 13 antikūnai ir jų naudojimai
|
US7435799B2
(en)
*
|
2004-01-08 |
2008-10-14 |
Applied Molecular Evolution |
TNF-α binding molecules
|
US7625549B2
(en)
*
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
AU2005227313A1
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through V gene manipulation
|
TW201705980A
(zh)
*
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
CN100427504C
(zh)
*
|
2004-06-02 |
2008-10-22 |
北京天广实生物技术有限公司 |
TNFα高亲和力嵌合抗体及其用途
|
US7501121B2
(en)
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
US20060039902A1
(en)
*
|
2004-08-05 |
2006-02-23 |
Young Deborah A |
Antagonizing interleukin-21 receptor activity
|
EP1807111A4
(de)
*
|
2004-10-08 |
2009-05-27 |
Abbott Biotech Ltd |
Infektion mit dem respiratorischen synzytial-virus
|
WO2007001420A2
(en)
*
|
2004-10-22 |
2007-01-04 |
Genencor International, Inc. |
Isolating human antibodies
|
EP2808033A1
(de)
|
2004-11-19 |
2014-12-03 |
Biogen Idec MA Inc. |
Behandlung multipler Sklerose
|
TR201901929T4
(tr)
|
2005-02-08 |
2019-03-21 |
Genzyme Corp |
TGFBeta'ya antikorlar.
|
WO2006088925A2
(en)
*
|
2005-02-14 |
2006-08-24 |
Wyeth |
Use of il17-f in diagnosis and therapy of airway inflammation
|
RU2007129263A
(ru)
*
|
2005-02-14 |
2009-03-20 |
Вайет (Us) |
Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение
|
DK2332408T3
(da)
|
2005-02-17 |
2013-12-02 |
Biogen Idec Inc |
Behandling af neurologiske sygdomme
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
WO2006122187A2
(en)
|
2005-05-10 |
2006-11-16 |
Biogen Idec Ma Inc. |
Treating and evaluating inflammatory disorders
|
AU2012254978C1
(en)
*
|
2005-05-16 |
2017-06-01 |
Abbvie Biotechnology Ltd |
Use of TNF inhibitor for treatment of erosive polyarthritis
|
NZ608319A
(en)
*
|
2005-05-16 |
2014-08-29 |
Abbvie Biotechnology Ltd |
Use of tnf inhibitor for treatment of erosive polyarthritis
|
CA2610960A1
(en)
*
|
2005-06-06 |
2006-12-14 |
Wyeth |
Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
|
AU2006255415B2
(en)
|
2005-06-07 |
2011-10-06 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Stable and soluble antibodies inhibiting TNFalpha
|
SG162788A1
(en)
|
2005-06-14 |
2010-07-29 |
Amgen Inc |
Self-buffering protein formulations
|
US20060286108A1
(en)
*
|
2005-06-16 |
2006-12-21 |
Bell Katherine A |
Topical compositions for the treatment of chronic wounds
|
AU2006261357A1
(en)
*
|
2005-06-17 |
2006-12-28 |
Zimmer Spine Austin, Inc. |
Improved method of treating degenerative spinal disorders
|
EP1896072A4
(de)
*
|
2005-06-24 |
2013-01-09 |
Univ Duke |
System zur direkten heilmittelverabreichung auf der basis wärmegesteuerter biopolymere
|
CN101595228A
(zh)
|
2005-07-21 |
2009-12-02 |
艾博特公司 |
包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法
|
TW200726776A
(en)
*
|
2005-07-29 |
2007-07-16 |
Friedrich Alexander University Of Erlangen Nuremberg |
CD33-specific single-chain immunotoxin and methods of use
|
CN101370525B
(zh)
|
2005-08-19 |
2013-09-18 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
US20070041905A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
EP2500359A3
(de)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
ES2542501T3
(es)
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
|
WO2007049286A1
(en)
*
|
2005-10-27 |
2007-05-03 |
Tata Memorial Centre |
A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma
|
AU2006337105B2
(en)
|
2005-11-01 |
2013-05-02 |
Abbvie Biotechnology Ltd |
Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
EP2289909B1
(de)
|
2005-11-30 |
2014-10-29 |
AbbVie Inc. |
Screeningsverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannten nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern
|
CN102898519B
(zh)
|
2005-11-30 |
2015-10-28 |
Abbvie公司 |
抗淀粉样β蛋白的单克隆抗体及其用途
|
US8178495B2
(en)
|
2008-06-27 |
2012-05-15 |
Duke University |
Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
|
JP2009525946A
(ja)
|
2005-12-20 |
2009-07-16 |
デューク・ユニヴァーシティ |
増強された薬理学的性質を有する活性物質を送達するための方法および組成物
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
JP5259423B2
(ja)
|
2006-02-01 |
2013-08-07 |
セファロン・オーストラリア・ピーティーワイ・リミテッド |
ドメイン抗体構築物
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
EP3088410A3
(de)
|
2006-04-05 |
2016-12-28 |
AbbVie Biotechnology Ltd |
Antikörperreinigung
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
EP2666478A3
(de)
|
2006-04-10 |
2014-10-22 |
AbbVie Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von Schuppenflechte
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
EP2012586A4
(de)
|
2006-04-10 |
2010-08-18 |
Abbott Biotech Ltd |
Anwendungen und zusammensetzungen zur behandlung von morbus bechterew
|
EP2010214A4
(de)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
US20080131374A1
(en)
*
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
US20080311043A1
(en)
*
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
US20100021451A1
(en)
*
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
NZ572765A
(en)
|
2006-06-30 |
2012-08-31 |
Abbott Biotech Ltd |
Automatic injection device with rod driving syringe longitudinally split with radially compressible pair of wings along its length
|
HUE052220T2
(hu)
|
2006-09-08 |
2021-04-28 |
Abbvie Bahamas Ltd |
Interleukin-13 kötõfehérjék
|
MX346523B
(es)
|
2006-09-13 |
2017-03-23 |
Abbvie Inc |
Mejoras de cultivos celulares.
|
EP2500415A1
(de)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Verbesserungen an Zellkulturen
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
NZ597676A
(en)
*
|
2006-10-27 |
2013-07-26 |
Abbvie Biotechnology Ltd |
Crystalline anti-hTNFalpha antibodies
|
US8754107B2
(en)
|
2006-11-17 |
2014-06-17 |
Abbvie Inc. |
Aminopyrrolidines as chemokine receptor antagonists
|
WO2008064321A2
(en)
|
2006-11-21 |
2008-05-29 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating chronic inflammatory diseases using a gm-csf antagonist
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
WO2008082651A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Dual-specific il-1a/ il-1b antibodies
|
US7776331B1
(en)
|
2007-01-16 |
2010-08-17 |
Abbott Laboratories |
Methods of treating plaque psoriasis
|
JP2008209378A
(ja)
*
|
2007-01-31 |
2008-09-11 |
Fujifilm Corp |
バイオセンサー基板
|
DK2148691T3
(en)
|
2007-02-05 |
2015-08-17 |
Apellis Pharmaceuticals Inc |
Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
IN2009DN05758A
(de)
*
|
2007-03-12 |
2015-07-24 |
Esbatech Ag |
|
TW200902064A
(en)
*
|
2007-03-28 |
2009-01-16 |
Wyeth Corp |
Methods and compositions for modulating IL-17F/IL-17A biological activity
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
WO2008124858A2
(en)
*
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
WO2008150491A2
(en)
|
2007-05-31 |
2008-12-11 |
Abbott Laboratories |
BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
|
WO2008150490A2
(en)
*
|
2007-06-01 |
2008-12-11 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriasis and crohn's disease
|
CA2688433A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
CA2683801A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
EP2171451A4
(de)
*
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
Verfahren zur behandlung juveniler idiopathischer arthritis
|
PT2170390T
(pt)
|
2007-06-14 |
2019-02-12 |
Biogen Ma Inc |
Formulações com anticorpo natalizumab
|
CN106366192B
(zh)
*
|
2007-06-25 |
2020-03-27 |
艾斯巴技术-诺华有限责任公司 |
修饰抗体的方法和具有改善的功能性质的修饰抗体
|
KR101530723B1
(ko)
*
|
2007-06-25 |
2015-06-22 |
에스바테크 - 어 노바티스 컴파니 엘엘씨 |
단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
|
EP2173380A4
(de)
*
|
2007-07-13 |
2011-08-31 |
Abbott Biotech Ltd |
VERFAHREN UND ZUSAMMENSETZUNGEN ZUR PULMONALEN VERABREICHUNG EINES TNFa-HEMMERS
|
RU2010107994A
(ru)
|
2007-08-08 |
2011-09-20 |
Эбботт Лэборетриз (Us) |
Композиции и способы кристаллизации антител
|
AU2008289441A1
(en)
|
2007-08-22 |
2009-02-26 |
Cytomx Therapeutics, Inc. |
Activatable binding polypeptides and methods of identification and use thereof
|
CN101802005B
(zh)
*
|
2007-08-28 |
2015-09-16 |
艾伯维生物技术有限公司 |
包括关于阿达木单抗的结合蛋白质的组合物和方法
|
JP2009082033A
(ja)
*
|
2007-09-28 |
2009-04-23 |
Kaneka Corp |
完全ヒト型抗体生産法
|
US20090136465A1
(en)
|
2007-09-28 |
2009-05-28 |
Intrexon Corporation |
Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
|
CA2706700A1
(en)
|
2007-11-08 |
2009-05-14 |
Cytimmune Sciences, Inc. |
Compositions and methods for generating antibodies
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
TW200938221A
(en)
|
2007-11-30 |
2009-09-16 |
Abbott Lab |
Protein formulations and methods of making same
|
WO2009086550A1
(en)
*
|
2008-01-03 |
2009-07-09 |
Abbott Laboratories |
Predicting long-term efficacy of a compound in the treatment of psoriasis
|
NZ601913A
(en)
|
2008-01-15 |
2014-02-28 |
Abbott Gmbh & Co Kg |
Powdered protein compositions and methods of making same
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
JP5604311B2
(ja)
|
2008-03-13 |
2014-10-08 |
バイオテスト・アクチエンゲゼルシヤフト |
疾患治療剤
|
KR20100135807A
(ko)
|
2008-03-13 |
2010-12-27 |
바이오테스트 아게 |
질병 치료제
|
BRPI0909048A2
(pt)
|
2008-03-13 |
2015-11-24 |
Biotest Ag |
composição farmacêutica, e, método de tratamento de uma doença autoimune
|
KR20100126515A
(ko)
|
2008-03-18 |
2010-12-01 |
아보트 러보러터리즈 |
건선의 치료방법
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
EP2113568A1
(de)
|
2008-04-30 |
2009-11-04 |
Deutsches Rheuma-Forschungszentrum Berlin |
Knock-in-Maus zur Modellierung einer menschlichen TNFalpha-Blockade
|
JP5890174B2
(ja)
|
2008-05-09 |
2016-03-22 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
終末糖化産物受容体(rage)に対する抗体及びその使用
|
CN102036683A
(zh)
*
|
2008-05-20 |
2011-04-27 |
株式会社钟化 |
细胞毒性组合物
|
US9109026B2
(en)
|
2008-06-03 |
2015-08-18 |
Abbvie, Inc. |
Dual variable domain immunoglobulins and uses thereof
|
RU2010153580A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
MX347972B
(es)
|
2008-06-25 |
2017-05-22 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles que inhiben el vegf.
|
PL3241843T3
(pl)
|
2008-06-25 |
2021-12-27 |
Novartis Ag |
Optymalizacja rozpuszczalności cząsteczek immunowiążących
|
HUE039692T2
(hu)
|
2008-06-25 |
2019-01-28 |
Esbatech Alcon Biomed Res Unit |
TNF-et gátló stabil és oldható ellenanyagok
|
WO2010003118A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
Tgf-b antagonist multi-target binding proteins
|
BRPI0915825A2
(pt)
|
2008-07-08 |
2015-11-03 |
Abbott Lab |
proteínas de ligação à prostaglandina e2 usos das mesmas
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
AU2009285585A1
(en)
*
|
2008-08-28 |
2010-03-04 |
Wyeth Llc |
Uses of IL-22, IL-17, and IL-1 family cytokines in autoimmune diseases
|
DK2340039T3
(en)
*
|
2008-10-07 |
2016-02-29 |
Univ Nat Cheng Kung |
Use of IL-20 antagonists for treating osteoporosis
|
CN102271707B
(zh)
|
2008-10-29 |
2015-04-08 |
阿布林克斯公司 |
单域抗原结合性分子的制剂
|
JP6113404B2
(ja)
|
2008-10-29 |
2017-04-12 |
アブリンクス エン.ヴェー. |
単一ドメイン抗原結合分子の精製方法
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
CN101419224B
(zh)
*
|
2008-11-06 |
2012-08-22 |
复旦大学附属华山医院 |
一种同时测定人血浆中霉酚酸酯、霉酚酸及其代谢物的方法
|
NZ606283A
(en)
*
|
2008-11-28 |
2014-08-29 |
Abbvie Inc |
Stable antibody compositions and methods for stabilizing same
|
CN101766602B
(zh)
*
|
2008-12-30 |
2012-01-11 |
中国医学科学院血液病医院(血液学研究所) |
取代芳香基腙类化合物在作为肿瘤坏死因子抑制剂药物方面的应用
|
CA2750155A1
(en)
|
2008-12-30 |
2010-07-08 |
Centocor Ortho Biotech Inc. |
Serum markers predicting clinical response to anti-tnf.alpha. antibodiesin patients with ankylosing spondylitis
|
US20100189651A1
(en)
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
RU2011138951A
(ru)
*
|
2009-02-23 |
2013-03-27 |
Сайтомкс Терапьютикс, Инк. |
Пропротеины и способы их применения
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
TWI541021B
(zh)
|
2009-03-05 |
2016-07-11 |
艾伯維有限公司 |
Il-17結合蛋白
|
RU2595379C2
(ru)
|
2009-04-16 |
2016-08-27 |
АббВай Биотерапеутикс Инк. |
АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
|
CN101875694B
(zh)
*
|
2009-04-28 |
2014-04-02 |
中国医学科学院基础医学研究所 |
TNFα的抗体及其用途
|
JP5677411B2
(ja)
|
2009-04-29 |
2015-02-25 |
アッヴィ バイオテクノロジー リミテッド |
自動注入機器
|
CA2760185A1
(en)
*
|
2009-05-04 |
2010-11-11 |
Abbott Biotechnology Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha antibodies
|
WO2010132872A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Novimmune S.A |
Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
SG10201407329RA
(en)
*
|
2009-08-14 |
2015-01-29 |
Phasebio Pharmaceuticals Inc |
Modified vasoactive intestinal peptides
|
US20110044981A1
(en)
*
|
2009-08-21 |
2011-02-24 |
Spangler Rhyannon |
Methods and compositions for treatment of pulmonary fibrotic disorders
|
CN105131112A
(zh)
|
2009-08-29 |
2015-12-09 |
Abbvie公司 |
治疗用dll4结合蛋白
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
TW201127400A
(en)
*
|
2009-09-14 |
2011-08-16 |
Abbott Lab |
Methods for treating psoriasis
|
CA2775291A1
(en)
*
|
2009-09-24 |
2011-03-31 |
Xbiotech, Inc. |
Methods, compositions, and kits for reducing anti-antibody responses
|
EP2480888B1
(de)
|
2009-09-25 |
2016-11-30 |
XOMA Technology Ltd. |
Screening-verfahren
|
CN102666875A
(zh)
|
2009-10-15 |
2012-09-12 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
CN102695955B
(zh)
*
|
2009-10-26 |
2015-03-18 |
雀巢产品技术援助有限公司 |
检测抗-tnf药物和自身抗体的试验
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
MX2012005117A
(es)
|
2009-10-30 |
2012-06-14 |
Abbott Lab |
Construcciones de sorf y expresion de gen multiple.
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
WO2011058087A1
(en)
|
2009-11-11 |
2011-05-19 |
Gentian As |
Immunoassay for assessing related analytes of different origin
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
WO2011068927A2
(en)
*
|
2009-12-04 |
2011-06-09 |
Abbott Laboratories |
11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
|
AU2010329955A1
(en)
|
2009-12-08 |
2012-05-24 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
|
NZ600069A
(en)
|
2009-12-15 |
2015-02-27 |
Abbvie Biotechnology Ltd |
Improved firing button for automatic injection device
|
JP2013514388A
(ja)
*
|
2009-12-16 |
2013-04-25 |
フィリップ ボッシュ, |
間質性膀胱炎の処置の方法
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
WO2011092715A2
(en)
*
|
2010-01-27 |
2011-08-04 |
Tata Memorial Centre |
Method for in-vivo binding of chromatin fragments
|
US20120014956A1
(en)
|
2010-02-02 |
2012-01-19 |
Hartmut Kupper |
Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
|
CN102167741B
(zh)
*
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗TNF-α单克隆抗体、其制备方法及用途
|
KR20180044441A
(ko)
|
2010-03-02 |
2018-05-02 |
애브비 인코포레이티드 |
치료학적 dll4 결합 단백질
|
NZ603045A
(en)
|
2010-04-07 |
2014-11-28 |
Abbvie Inc |
Tnf-alpha binding proteins
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
DK3466977T3
(en)
|
2010-04-16 |
2022-04-11 |
Biogen Ma Inc |
Anti-vla-4-antistoffer
|
ES2727275T3
(es)
|
2010-04-21 |
2019-10-15 |
Abbvie Biotechnology Ltd |
Dispositivo automático de inyección portátil para la liberación controlada de agentes terapéuticos
|
LT2571532T
(lt)
|
2010-05-14 |
2017-08-10 |
Abbvie Inc. |
Il-1 surišantys baltymai
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
ES2685607T3
(es)
|
2010-06-03 |
2018-10-10 |
Abbvie Biotechnology Ltd |
Usos y composiciones para el tratamiento de la hidradenitis supurativa (HS)
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
PE20131412A1
(es)
|
2010-08-03 |
2014-01-19 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CA2808187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbvie Inc. |
Amyloid-beta binding proteins
|
PT3333188T
(pt)
|
2010-08-19 |
2022-03-28 |
Zoetis Belgium S A |
Anticorpos de anti-ngf e a sua utilização
|
TW201211252A
(en)
|
2010-08-26 |
2012-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
AR083495A1
(es)
|
2010-10-22 |
2013-02-27 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
BR112013009093B1
(pt)
|
2010-10-29 |
2022-04-19 |
Abbvie Inc |
Processo para a preparação de uma dispersão sólida contendo um agente indutor de apoptose
|
AU2011323521A1
(en)
*
|
2010-11-02 |
2013-06-20 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
AU2011325974B2
(en)
|
2010-11-11 |
2016-10-27 |
Abbvie Biotechnology Ltd. |
Improved high concentration anti-TNFalpha antibody liquid formulations
|
RU2593231C2
(ru)
|
2010-11-23 |
2016-08-10 |
ЭббВи Айэленд Анлимитед Компани |
Способы лечения с использованием селективных ингибиторов bcl-2
|
NO2643322T3
(de)
|
2010-11-23 |
2018-01-27 |
|
|
AR084210A1
(es)
|
2010-12-08 |
2013-05-02 |
Abbott Lab |
PROTEINAS DE UNION AL TNF-a
|
PE20141060A1
(es)
|
2010-12-21 |
2014-09-26 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
EP2490024A1
(de)
|
2010-12-22 |
2012-08-22 |
Proteomika, S.L. |
Verfahren zur Optimierung der Behandlung von Patienten mit biologischen Arzneimitteln
|
KR101853607B1
(ko)
|
2011-01-24 |
2018-05-03 |
애브비 바이오테크놀로지 리미티드 |
주사기로부터 니들 실드의 제거 및 자동 주사 디바이스들
|
EP2667918B1
(de)
|
2011-01-24 |
2017-03-01 |
AbbVie Biotechnology Ltd |
Automatische injektionsvorrichtungen mit übersrpitzten griffflächen
|
US8992477B2
(en)
|
2011-01-24 |
2015-03-31 |
Elcam Agricultural Cooperative Association Ltd. |
Injector
|
RU2455025C1
(ru)
*
|
2011-02-10 |
2012-07-10 |
Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") |
Способ фармакологической коррекции ишемии конечности смесью растворов гомеопатических разведений
|
US20130344081A1
(en)
|
2011-03-07 |
2013-12-26 |
The University Of Tokushima |
Method of treating amyotrophic lateral sclerosis
|
CA2829773A1
(en)
|
2011-03-18 |
2012-09-27 |
Abbvie Inc. |
Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof
|
TWI743461B
(zh)
|
2011-03-28 |
2021-10-21 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
CN105413022A
(zh)
|
2011-03-29 |
2016-03-23 |
艾伯维公司 |
自动注射装置中的改进的护罩展开
|
ES2605817T3
(es)
|
2011-04-21 |
2017-03-16 |
Abbvie Inc. |
Dispositivo de inyección automático portátil
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
CA2837169C
(en)
|
2011-05-24 |
2021-11-09 |
Zyngenia, Inc. |
Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
|
WO2012166971A2
(en)
|
2011-05-31 |
2012-12-06 |
Biogen Idec Ma Inc. |
Method of assessing risk of pml
|
CA2873553C
(en)
|
2011-06-06 |
2020-01-28 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
AU2012283039A1
(en)
|
2011-07-13 |
2014-01-30 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-IL-13 antibodies
|
GB201112429D0
(en)
*
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
WO2013019889A2
(en)
*
|
2011-08-01 |
2013-02-07 |
Avaxia Biologics, Inc. |
Bovine polyclonal antibody specific for human tnf
|
WO2013056851A2
(en)
*
|
2011-10-20 |
2013-04-25 |
Esbatech - A Novartis Company Llc |
Stable multiple antigen-binding antibody
|
AR088512A1
(es)
|
2011-10-24 |
2014-06-18 |
Abbvie Inc |
Anticuerpos dirigidos contra el tnf
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素(sclerostin)之免疫結合物
|
KR20140084254A
(ko)
|
2011-10-24 |
2014-07-04 |
애브비 인코포레이티드 |
Tnf 및 il-17로 향하는 이특이성 면역결합제
|
CA2857597A1
(en)
|
2011-11-30 |
2013-06-06 |
AbbVie Deutschland GmbH & Co. KG |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
EP2791175A2
(de)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
EP2791173B1
(de)
|
2011-12-14 |
2020-07-29 |
AbbVie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
EP2791171A1
(de)
|
2011-12-16 |
2014-10-22 |
Synthon Biopharmaceuticals B.V. |
Expression sekretorischer iga-antikörper in wasserlinse
|
US20130171059A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對il-13及/或il-17之雙特異性結合蛋白
|
KR102129234B1
(ko)
|
2012-01-27 |
2020-07-02 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
신경돌기 변성과 연관된 질환의 진단 및 치료를 위한 조성물 및 방법
|
SG10201609982PA
(en)
|
2012-03-07 |
2017-01-27 |
Cadila Healthcare Ltd |
Pharmaceutical formulations of tnf-alpha anitbodies
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
EP2657334B1
(de)
|
2012-04-26 |
2016-07-06 |
GeneFrontier Corporation |
Effizientes Verfahren zur Anzeige eines Proteinmultimers
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
PL2859017T3
(pl)
|
2012-06-08 |
2019-07-31 |
Sutro Biopharma, Inc. |
Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
CN104981254B
(zh)
|
2012-08-31 |
2018-05-22 |
苏特罗生物制药公司 |
含有叠氮基的经修饰的氨基酸
|
AU2013309506A1
(en)
|
2012-09-02 |
2015-03-12 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
TW202042841A
(zh)
|
2012-09-07 |
2020-12-01 |
美商柯赫勒斯生物科學有限公司 |
阿達木單抗(adalimumab)之穩定水性調配物
|
WO2014047222A2
(en)
*
|
2012-09-19 |
2014-03-27 |
Abbvie Biotherapeutics Inc. |
Methods for identifying antibodies with reduced immunogenicity
|
TW202033215A
(zh)
|
2012-11-01 |
2020-09-16 |
美商艾伯維有限公司 |
穩定雙重可變區域免疫球蛋白蛋白質調配物
|
KR20190107184A
(ko)
|
2012-11-01 |
2019-09-18 |
애브비 인코포레이티드 |
항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
|
TWI675044B
(zh)
|
2012-11-14 |
2019-10-21 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
US9856319B2
(en)
|
2012-12-28 |
2018-01-02 |
Abbvie Inc. |
Monovalent binding proteins
|
US20140219913A1
(en)
|
2012-12-28 |
2014-08-07 |
Abbvie, Inc. |
Dual Specific Binding Proteins Having a Receptor Sequence
|
KR101759687B1
(ko)
|
2013-01-25 |
2017-07-19 |
타이몬, 엘엘씨 |
순환하는 생물활성 가용성 tnf의 선택적 감소를 위한 조성물 및 tnf-매개 질환의 치료 방법
|
ES2755181T3
(es)
|
2013-02-13 |
2020-04-21 |
Lab Francais Du Fractionnement |
Anticuerpos anti-TNF-alfa altamente galactosilados y usos de los mismos
|
WO2014143205A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014159579A1
(en)
*
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
BR112015017307A2
(pt)
|
2013-03-14 |
2017-11-21 |
Abbvie Inc |
composições de espécies com baixa acidez e métodos para produção e uso das mesmas
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
EP3564384A1
(de)
|
2013-03-14 |
2019-11-06 |
Abbott Laboratories |
Monoklonale antikörper gegen hcv-core lipid-bindender domäne
|
CN105228649B
(zh)
|
2013-03-14 |
2019-01-18 |
雅培制药有限公司 |
Hcv抗原-抗体组合测定和方法以及用在其中的组合物
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
AU2014240431A1
(en)
|
2013-03-14 |
2015-08-27 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
JP2016517277A
(ja)
|
2013-03-15 |
2016-06-16 |
アッヴィ・インコーポレイテッド |
TNFαに対して指向された二重特異的結合タンパク質
|
CN105263964A
(zh)
*
|
2013-05-22 |
2016-01-20 |
美特博利工程实验室株式会社 |
抗-TNF-α/CXCL10双靶向抗体及其应用
|
ES2753419T3
(es)
|
2013-06-07 |
2020-04-08 |
Univ Duke |
Inhibidores del factor H del complemento
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
US20150038454A1
(en)
*
|
2013-07-31 |
2015-02-05 |
Mary Malast |
Antimicrobial compositions and methods of use
|
RU2016107435A
(ru)
|
2013-09-13 |
2017-10-18 |
Дженентек, Инк. |
Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
|
SG11201601823TA
(en)
|
2013-09-13 |
2016-04-28 |
Genentech Inc |
Methods and compositions comprising purified recombinant polypeptides
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US20150125397A1
(en)
|
2013-10-06 |
2015-05-07 |
Abbvie Inc. |
Dual specific binding proteins directed against immune cell receptors and autoantigens
|
EP3055298B1
(de)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
|
EP3057616B1
(de)
|
2013-10-16 |
2020-03-11 |
Outlook Therapeutics, Inc. |
Pufferformulierungen für verstärkte antikörperstabilität
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
US20150203592A1
(en)
|
2013-12-02 |
2015-07-23 |
Abbvie Inc. |
Compositions and methods for treating osteoarthritis
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
EP3757224A3
(de)
|
2014-02-27 |
2021-03-17 |
Biogen MA Inc. |
Verfahren zur beurteilung eines pml-risikos
|
JP6293907B2
(ja)
|
2014-03-10 |
2018-03-14 |
リヒター ゲデオン エヌワイアールティー. |
プレクリーニング工程を用いた免疫グロブリンの精製
|
TW202214691A
(zh)
|
2014-03-21 |
2022-04-16 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
AR099625A1
(es)
*
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
WO2015151115A1
(en)
*
|
2014-04-02 |
2015-10-08 |
Intas Pharmaceuticals Limited |
Liquid pharmaceutical composition of adalimumab
|
WO2015172046A1
(en)
|
2014-05-08 |
2015-11-12 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
EP2946766B1
(de)
|
2014-05-23 |
2016-03-02 |
Ares Trading S.A. |
Flüssige pharmazeutische Zusammensetzung
|
EP2946767B1
(de)
|
2014-05-23 |
2016-10-05 |
Ares Trading S.A. |
Flüssige pharmazeutische Zusammensetzung
|
SI2946765T1
(sl)
|
2014-05-23 |
2016-11-30 |
Ares Trading S.A. |
Tekoči farmacevtski sestavek
|
FR3022462B1
(fr)
*
|
2014-06-18 |
2018-04-27 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Composition orale d'anticorps anti-tnfalpha
|
US20170183376A1
(en)
|
2014-06-24 |
2017-06-29 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
CN106459192B
(zh)
*
|
2014-06-30 |
2021-08-03 |
默克专利股份公司 |
具有pH依赖性抗原结合的抗TNFa抗体
|
WO2016004197A1
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
WO2016007764A1
(en)
|
2014-07-09 |
2016-01-14 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
|
EA202193002A2
(ru)
|
2014-09-03 |
2022-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Соединение, нацеленное на ил-23a и фно-альфа, и его применение
|
US10435464B1
(en)
|
2014-09-05 |
2019-10-08 |
Coherus Biosciences, Inc. |
Methods for making recombinant proteins
|
HUP1400510A1
(hu)
|
2014-10-28 |
2016-05-30 |
Richter Gedeon Nyrt |
Gyógyászati TNFalfa ellenes antitest készítmény
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
US20170360929A1
(en)
|
2014-12-23 |
2017-12-21 |
Pfizer Inc. |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
EP3085709B1
(de)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanisierte antikörper gegen menschliches rankl, pharmazeutische zusammensetzung und verwendung davon
|
WO2016118707A1
(en)
|
2015-01-21 |
2016-07-28 |
Oncobiologics, Inc. |
Modulation of charge variants in a monoclonal antibody composition
|
EP3053572A1
(de)
|
2015-02-06 |
2016-08-10 |
Ares Trading S.A. |
Flüssige pharmazeutische Zusammensetzung
|
EP3256151B1
(de)
|
2015-02-09 |
2020-08-05 |
Phasebio Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von muskelerkrankungen und -störungen
|
CN105777905B
(zh)
*
|
2015-03-24 |
2019-06-25 |
广东东阳光药业有限公司 |
一种全人源抗TNF-α单克隆抗体及其应用
|
EP3078675A1
(de)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind
|
WO2016179469A1
(en)
*
|
2015-05-07 |
2016-11-10 |
Abbvie Inc. |
Methods and compositions for diagnosing and treating inflammatory bowel disease
|
RU2715597C2
(ru)
|
2015-05-29 |
2020-03-02 |
Эббви Инк. |
Антитела к cd40 и способы их применения
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
HU231463B1
(hu)
|
2015-08-04 |
2024-01-28 |
Richter Gedeon Nyrt. |
Módszer rekombináns proteinek galaktóz tartalmának növelésére
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
US11583584B1
(en)
|
2015-10-28 |
2023-02-21 |
Coherus Biosciences, Inc. |
Stable protein compositions and methods of their use
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
EP3411401A1
(de)
|
2016-02-03 |
2018-12-12 |
Oncobiologics, Inc. |
Pufferformulierungen für verstärkte antikörperstabilität
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
CA3016870A1
(en)
*
|
2016-03-17 |
2017-09-21 |
Numab Innovation Ag |
Anti-tnf.alpha.-antibodies and functional fragments thereof
|
RS61374B1
(sr)
*
|
2016-03-17 |
2021-02-26 |
Tillotts Pharma Ag |
Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
|
JP2019513737A
(ja)
|
2016-04-08 |
2019-05-30 |
ギリアード サイエンシーズ, インコーポレイテッド |
がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
|
WO2017184880A1
(en)
|
2016-04-20 |
2017-10-26 |
Coherus Biosciences, Inc. |
A method of filling a container with no headspace
|
CA3021334C
(en)
|
2016-04-27 |
2022-11-29 |
Abbvie Inc. |
Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
|
WO2017210471A1
(en)
|
2016-06-02 |
2017-12-07 |
Abbvie Inc. |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
LT3458479T
(lt)
|
2016-06-08 |
2021-02-25 |
Abbvie Inc. |
Anti-b7-h3 antikūnai ir antikūnų vaisto konjugatai
|
BR112018075653A2
(pt)
|
2016-06-08 |
2019-08-27 |
Abbvie Inc |
anticorpos anti-b7-h3 e conjugados anticorpo fármaco
|
JP2019521975A
(ja)
|
2016-06-08 |
2019-08-08 |
アッヴィ・インコーポレイテッド |
抗egfr抗体薬物コンジュゲート
|
CA3027033A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
JP2019521973A
(ja)
|
2016-06-08 |
2019-08-08 |
アッヴィ・インコーポレイテッド |
抗bh7−h3抗体及び抗体薬物コンジュゲート
|
WO2017214233A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
EP3472197A1
(de)
|
2016-06-15 |
2019-04-24 |
Sutro Biopharma, Inc. |
Antikörper mit manipulierten ch2-domänen, zusammensetzungen davon und verfahren zur verwendung davon
|
WO2018018613A1
(zh)
|
2016-07-29 |
2018-02-01 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
US10751324B2
(en)
|
2016-09-02 |
2020-08-25 |
The University Of Chicago |
Treatment of TNF- alpha cytotoxicity
|
EP3512875A2
(de)
*
|
2016-09-15 |
2019-07-24 |
Quadrucept Bio Limited |
Multimere, tetramere und oktamere
|
CA3036714A1
(en)
|
2016-10-03 |
2018-04-12 |
Abbott Laboratories |
Improved methods of assessing uch-l1 status in patient samples
|
WO2018075408A1
(en)
|
2016-10-17 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
|
CN109982685B
(zh)
|
2016-10-21 |
2022-03-11 |
美国安进公司 |
药物配制品及其制备方法
|
WO2018102594A1
(en)
|
2016-12-01 |
2018-06-07 |
Alexion Pharmaceuticals, Inc. |
Methods of treating solid tumors with anti-cd200 antibodies
|
CN110087530A
(zh)
|
2016-12-07 |
2019-08-02 |
普罗根尼蒂公司 |
胃肠道检测方法、装置和系统
|
BR112019011689A2
(pt)
|
2016-12-14 |
2019-10-22 |
Progenity Inc |
tratamento de uma doença do trato gastrointestinal com um inibidor de tnf
|
WO2018112334A1
(en)
*
|
2016-12-16 |
2018-06-21 |
Bluefin Biomedicine, Inc. |
Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
AU2018207367B2
(en)
|
2017-01-11 |
2024-02-15 |
Celltrion Inc. |
Stable Liquid Formula
|
TWI787230B
(zh)
|
2017-01-20 |
2022-12-21 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
TWI788321B
(zh)
|
2017-01-20 |
2023-01-01 |
美商健臻公司 |
骨靶向抗體
|
WO2018140121A1
(en)
|
2017-01-30 |
2018-08-02 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
|
KR20240038148A
(ko)
|
2017-02-07 |
2024-03-22 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
US11608357B2
(en)
|
2018-08-28 |
2023-03-21 |
Arecor Limited |
Stabilized antibody protein solutions
|
EP3372241A1
(de)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Flüssige pharmazeutische zusammensetzung
|
EP3372242A1
(de)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Flüssige pharmazeutische zusammensetzung
|
CA3052513A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
CN110382052A
(zh)
|
2017-03-26 |
2019-10-25 |
Mapi医药公司 |
用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
|
WO2018184692A1
(en)
|
2017-04-07 |
2018-10-11 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
JP7344797B2
(ja)
|
2017-04-15 |
2023-09-14 |
アボット・ラボラトリーズ |
早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
AU2018272054A1
(en)
|
2017-05-25 |
2019-09-26 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
BR112019025313A2
(pt)
|
2017-05-30 |
2020-06-23 |
Abbott Laboratories |
Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i
|
EP3649474A1
(de)
|
2017-07-03 |
2020-05-13 |
Abbott Laboratories |
Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
DK3658192T3
(da)
|
2017-12-01 |
2021-06-21 |
Abbvie Inc |
Glucocorticoid-receptoragonist og immunokonjugater deraf
|
CN109879962B
(zh)
*
|
2017-12-06 |
2022-10-11 |
北京科立思维生物科技有限公司 |
抗tnf单链抗体、抗il-6单链抗体及其融合蛋白及其应用
|
BR112020010085A2
(pt)
|
2017-12-09 |
2020-10-13 |
Abbott Laboratories |
métodos para auxiliar no diagnóstico e avaliar uma lesão cerebral traumática em um indivíduo humano usando uma combinação de gfap e uch-l1
|
CA3067057A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
MX2020009526A
(es)
|
2018-03-12 |
2020-10-28 |
Zoetis Services Llc |
Anticuerpos anti-ngf y metodos de estos.
|
JP7331000B2
(ja)
|
2018-03-26 |
2023-08-22 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体c3転換酵素のプロテアーゼ活性を測定するためのスループットの高い方法
|
KR20210027352A
(ko)
|
2018-06-04 |
2021-03-10 |
바이오젠 엠에이 인코포레이티드 |
감소된 효과기 기능을 갖는 항-vla-4 항체
|
US20230312700A1
(en)
|
2018-06-20 |
2023-10-05 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
EP3817737A1
(de)
|
2018-07-03 |
2021-05-12 |
Novartis AG |
Verfahren zur behandlung oder auswahl einer behandlung für ein gegen tnf-inhibitor resistentes subjekt unter verwendung eines nlrp3-antagonisten
|
CN113329769A
(zh)
|
2018-10-11 |
2021-08-31 |
斯克里普斯研究学院 |
具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
|
US20220387397A1
(en)
|
2018-10-24 |
2022-12-08 |
Novartis Ag |
Compounds and compositions for treating conditions associated with nlrp activity
|
AR117192A1
(es)
*
|
2018-11-05 |
2021-07-21 |
Beijing Hanmi Pharmaceutical Co Ltd |
ANTICUERPO BIESPECÍFICO HETERODIMÉRICO SIMILAR EN ESTRUCTURA AL ANTICUERPO NATURAL ANTI-TNFa / ANTI-IL-17A, Y MÉTODO PARA SU PREPARACIÓN
|
HUP1800376A2
(hu)
|
2018-11-07 |
2020-05-28 |
Richter Gedeon Nyrt |
Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
|
US20230024859A1
(en)
|
2018-11-13 |
2023-01-26 |
Novartis Ag |
Compounds and compositions for treating conditions associated with nlrp activity
|
EP3880673B1
(de)
|
2018-11-13 |
2024-01-03 |
Novartis AG |
Verbindungen und zusammensetzungen zur behandlung von erkrankungen in zusammenhang mit nlrp-aktivität
|
EP3883635A1
(de)
|
2018-11-19 |
2021-09-29 |
Progenity, Inc. |
Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
WO2020132844A1
(zh)
|
2018-12-25 |
2020-07-02 |
中国医学科学院基础医学研究所 |
炎性相关疾病防治的小rna药物及其组合
|
CN113316566A
(zh)
|
2019-01-22 |
2021-08-27 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
HUP1900112A1
(hu)
|
2019-04-04 |
2020-10-28 |
Richter Gedeon Nyrt |
Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelõzõ flokkulálás alkalmazásával
|
KR102323342B1
(ko)
*
|
2019-04-26 |
2021-11-08 |
주식회사 와이바이오로직스 |
IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
|
CN113874073A
(zh)
|
2019-05-23 |
2021-12-31 |
詹森生物科技公司 |
用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
|
WO2021002887A1
(en)
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
CN114401988A
(zh)
*
|
2019-07-09 |
2022-04-26 |
国家生物技术研究所公司 |
具有降低的免疫原性的抗体
|
EP3870261B1
(de)
|
2019-12-13 |
2024-01-31 |
Biora Therapeutics, Inc. |
Einnehmbare vorrichtung zur abgabe eines therapeutischen mittels an den magen-darm-trakt
|
FR3104582A1
(fr)
|
2019-12-17 |
2021-06-18 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Variants de l’adalimumab au potentiel immunogène réduit
|
WO2021159024A1
(en)
|
2020-02-05 |
2021-08-12 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
CN111944052B
(zh)
*
|
2020-08-26 |
2022-02-11 |
中国药科大学 |
抗TNF-α/PD-1双特异性抗体及其应用
|
CN112010970B
(zh)
*
|
2020-10-30 |
2021-01-12 |
迈威(上海)生物科技股份有限公司 |
一种去除重组表达抗体聚体和降解产物的方法
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
US11672929B2
(en)
|
2020-12-02 |
2023-06-13 |
Breathe Restore, Inc. |
Product delivery devices and methods
|
JP2023554200A
(ja)
|
2020-12-09 |
2023-12-26 |
エイチケー イノ.エヌ コーポレーション |
抗OX40L抗体、抗OX40L及び抗TNFαの二重特異性抗体、並びにこれらの用途
|
WO2022133325A2
(en)
*
|
2020-12-18 |
2022-06-23 |
Kindred Biosciences, Inc. |
Tnf alpha and ngf antibodies for veterinary use
|
EP4271998A1
(de)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CA3216585A1
(en)
|
2021-04-27 |
2022-11-03 |
Nathaniel SILVER |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
EP4329884A1
(de)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Nichtvirale dna-vektoren zur expression von anti-coronavirus-antikörpern und verwendungen davon
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2022271782A1
(en)
*
|
2021-06-22 |
2022-12-29 |
University Of Virginia Patent Foundation |
Compositions and methods for detecting and regulating fibronectin-integrin interactions and signaling
|
CN117500816A
(zh)
|
2021-08-26 |
2024-02-02 |
映恩生物制药(苏州)有限公司 |
一种甾体化合物及其缀合物
|
CA3230038A1
(en)
|
2021-08-31 |
2023-03-09 |
Hongwei Zhang |
Methods and systems of diagnosing brain injury
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
WO2024006681A1
(en)
*
|
2022-06-28 |
2024-01-04 |
Adafre Biosciences, Llc |
Anti-tnf-αlpha antibodies and compositions
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
CN116903738A
(zh)
*
|
2022-08-02 |
2023-10-20 |
北京绿竹生物技术股份有限公司 |
一种低甘露糖型抗人肿瘤坏死因子-α单抗及其用途
|
WO2024054934A1
(en)
|
2022-09-07 |
2024-03-14 |
Mdx Management Llc |
Shp-1 inhibitors for treating cancer
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|